Respiratory Viruses: A Persistent Threat – Insights into Pandemics, Burden, Diagnostics, Vaccines, Therapeutics, Resistance, and India's Path Forward

Over the decades, I've seen respiratory viruses evolve from seasonal nuisances to global catastrophes, reminding us time and again of our vulnerabilities. This review draws from historical pandemics like the 1918 Spanish flu, which claimed 50-100 million lives, to the recent COVID-19 saga with its 7 million reported deaths. We delve into the staggering morbidity—2.4 million deaths and 3.6 million hospitalizations in 2016 alone, disproportionately hitting low- and middleincome countries. Advances in multiplex PCR panels, such as BioFire and QIAstat-Dx, have sharpened our diagnostic edge, while whole-genome sequencing (WGS) via platforms like Illumina and Oxford Nanopore aids in tracking variants and outbreaks. Vaccines for influenza, SARS-CoV-2, and RSV offer hope, but limited antivirals and rising resistance mutations (e.g., H275Y in influenza neuraminidase) demand caution. In India, where resources are stretched, we must prioritize expanding diagnostic labs, adult vaccination policies, genomic surveillance, local R&D, and infection control. This isn't just academic—it's a call to action based on years of frontline experience in tropical settings where these viruses hit hardest.